Fig. 4: Alectinib-failure PDCs were resistant to multiple ALK-TKIs.

Cell viability of ALK-positive PDCs treated with the indicated concentration of a alectinib, b lorlatinib, c crizotinib, and d ceritinib for 72 h was measured (n = 3). Each point represents the mean ± SD of three replicates.